Hims & Hers Health agreed to purchase Australian digital health company Eucalyptus for $1.15 billion in cash. The transaction represents Hims & Hers’ largest deal to date and provides access to Eucalyptus’s platform in Australia and New Zealand, strengthening the company’s international reach. Shares of Hims & Hers climbed 1.2% following the announcements, reflecting investor confidence in the combined growth prospects. Management forecasts that the deal and new AI services will accelerate subscriber growth and drive revenue diversification over the next 12 to 18 months. Alongside the acquisition, Hims & Hers announced the rollout of AI-driven preventive care services, including menopause support, low testosterone monitoring and multi-cancer screening tests. These offerings aim to enhance the personalized digital health platform by integrating advanced diagnostics and tailored care pathways.